{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T03:40:53Z","timestamp":1792381253626,"version":"4.4.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the goal of opioid agonist therapy is typically understood by clinicians to be the cessation of the use of non-prescribed opioids, many people taking opioid agonist therapy continue to use other opioids. The purpose of this study was to explore how people who use both prescribed opioid agonist therapy and non-prescribed opioids understand their use of both agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An interpretative phenomenological analysis was conducted with ten participants recruited from harm reduction sites in Toronto who were concurrently using opioid agonist therapy and non-prescribed opioids. Semi-structured interviews were audio-recorded and transcribed verbatim. Data were analysed to explore participants\u2019 understanding of their use of both opioid agonist therapy and non-prescribed opioids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants had unique reasons for the use of opioid agonist therapy and non-prescribed opioids; while opioid agonist therapy is free, relatively safe, and helps control opioid withdrawal symptoms, non-prescribed opioids satisfy opioid cravings, ease physical and emotional pain, and can be used with more autonomy. The participants\u2019 relationships with different opioids are complicated, and some struggle to reconcile their use with their goals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Participants shared that opioid agonist therapy and non-prescribed opioids fill complementary roles in their lives, each presenting their own benefits and challenges. Their experiences highlight opportunities for improving the provision of opioid agonist therapy in order to make it more effective and acceptable for people who use non-prescribed opioids, which is a crucial strategy in combatting mortality from the opioid toxicity crisis. Opioid agonist therapy can thus be situated within the harm reduction continuum as a practice that can be beneficial whether or not it results in abstinence, and clinicians should offer tailored regimens that take patient preferences and goals into account.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00658-2","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:13:08Z","timestamp":1784736788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Experiences of non-prescribed opioid use during opioid agonist therapy: an interpretative phenomenological analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Sarah","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Werb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nav","family":"Persaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"658_CR1","unstructured":"Martins D, Greaves S, Tadrous M, Paterson M, Bandola D, Singh S, et al. Opioid use and related adverse events in Ontario [Internet]. 2016. Available from: https:\/\/odprn.ca\/rates-of-opioid-use-and-related-adverse-events-in-ontario-by-county\/."},{"key":"658_CR2","doi-asserted-by":"publisher","unstructured":"Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: a needs assessment for decision making support. 2019;100:18\u201328. Available from: https:\/\/doi.org\/10.1016\/j.jsat.2019.01.019.","DOI":"10.1016\/j.jsat.2019.01.019"},{"key":"658_CR3","doi-asserted-by":"crossref","unstructured":"McDonald R, Bech AB, Clausen T. Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences. 2023;23:1\u2013965. Available from: https:\/\/www.proquest.com\/docview\/2865362235\/abstract\/.","DOI":"10.1186\/s12913-023-09959-7"},{"key":"658_CR4","doi-asserted-by":"crossref","unstructured":"Gomes T, Martins D, Singh S, Mamdani MM, Dhalla IA, Paterson JM, et al. Opioid-related deaths in Ontario between 1991 and 2010. Toronto (ON): Ontario Drug Policy Research Network; 2014. Available from: https:\/\/www.odprn.ca.","DOI":"10.31027\/ODPRN.2014.02"},{"key":"658_CR5","unstructured":"Bromley L, Kahan M, Regenstreif L, Srivastava A, Wyman J. Methadone treatment for people who use fentanyl: Recommendations [Internet]. Toronto, ON: META:PHI; 2021. Available from: https:\/\/www.metaphi.ca\/wp-content\/uploads\/Guide_MethadoneForFentanyl.pdf."},{"key":"658_CR6","unstructured":"Kolla G, Fajber K. Safer Opioid Supply Program Evaluation: A comparison of SOS client outcomes from 2022 and 2023 [Internet]. London, ON; 2023. Available from: https:\/\/lihc.on.ca\/programs\/safer-opioid-supply-program\/."},{"key":"658_CR7","doi-asserted-by":"crossref","unstructured":"Mackay L, Kerr T, Fairbairn N, Grant C, Milloy M-J, Hayashi K. The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting. 2021;16:26. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33910630.","DOI":"10.1186\/s13722-021-00234-w"},{"key":"658_CR8","doi-asserted-by":"crossref","unstructured":"Smith CBR. A Users\u2019 Guide to \u2018Juice Bars\u2019 and \u2018Liquid Handcuffs. 2011;14:291\u2013309. Available from: https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/1206331211412238.","DOI":"10.1177\/1206331211412238"},{"key":"658_CR9","doi-asserted-by":"crossref","unstructured":"Smith JA, Jarman M, Osborn M. In: Murray M, Chamberlain K, editors. Doing interpretative phenomenological analysis. London: SAGE; 1999. pp. 218\u201340.","DOI":"10.4135\/9781446217870.n14"},{"key":"658_CR10","volume-title":"Interpretative phenomenological analysis. Smith JA","author":"JA Smith","year":"2003","unstructured":"Smith JA, Osborn M. Interpretative phenomenological analysis. Smith JA. editor. London: Sage; 2003."},{"key":"658_CR11","doi-asserted-by":"crossref","unstructured":"Davis EL, Kelly PJ, Deane FP, Baker AL, Buckingham M, Degan T et al. The relationship between patient-centered care and outcomes in specialist drug and alcohol treatment: A systematic literature review. 2020;41:216\u201331. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/08897077.2019.1671940.","DOI":"10.1080\/08897077.2019.1671940"},{"key":"658_CR12","doi-asserted-by":"publisher","DOI":"10.1037\/0000259-000","volume-title":"Interpretative phenomenological analysis","author":"JA Smith","year":"2022","unstructured":"Smith JA, Flowers P, Larkin M. Interpretative phenomenological analysis. Washington DC; Melbourne: SAGE Publications;: Los Angeles; London; New Delhi; Singapore; 2022."},{"key":"658_CR13","unstructured":"Thompson H, McDonald K, Maghsoudi N, Werb D. What\u2019s Contaminating Toronto\u2019s Drug Supply? Insights from Samples Checked by Toronto\u2019s Drug Checking Service: January 1 - December 31, 2021 [Internet]. Toronto; 2022 Aug. Available from: https:\/\/drugchecking.cdpe.org\/report\/whats-contaminating-torontos-drug-supply-insights-from-samples-checked-by-torontos-drug-checking-service-january-1-december-31-2021\/."},{"key":"658_CR14","doi-asserted-by":"publisher","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. 2017;357:j1550. Available from: https:\/\/doi.org\/10.1136\/bmj.j1550.","DOI":"10.1136\/bmj.j1550"},{"key":"658_CR15","doi-asserted-by":"crossref","unstructured":"Russell C, Lange S, Kouyoumdjian F, Butler A, Ali F. Opioid agonist treatment take-home doses (\u2018carries\u2019): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA? 2022;19:1\u201389. Available from: https:\/\/www.proquest.com\/docview\/2704106996\/abstract\/.","DOI":"10.1186\/s12954-022-00671-z"},{"key":"658_CR16","unstructured":"Lam V, Latreille S, McLeod A, Munro C, Wyman J, Zhang M. A new framework for methadone carries: A person-centered evidence-informed approach to methadone take-home carry dosing [Internet]. Toronto, ON: META:PHI; 2023. Available from: https:\/\/www.metaphi.ca\/wp-content\/uploads\/CarryPrinciples.pdf."},{"key":"658_CR17","doi-asserted-by":"crossref","unstructured":"Knopf A. Do patients addicted to fentanyl need higher doses of methadone or buprenorphine? 2022;34:1\u20137. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/adaw.33525.","DOI":"10.1002\/adaw.33525"},{"key":"658_CR18","doi-asserted-by":"publisher","unstructured":"Thakrar AP, Pytell JD, Stoller KB, Walters V, Weiss RD, Chander G. Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder. 2023;150:209055. Available from: https:\/\/doi.org\/10.1016\/j.josat.2023.209055.","DOI":"10.1016\/j.josat.2023.209055"},{"key":"658_CR19","doi-asserted-by":"crossref","unstructured":"Wyse J, Lovejoy T, Gordon A, Mackey K, Herreid-O\u2019Neill A, Morasco B. I\u2019m clean and sober, but not necessarily free: Perceptions of buprenorphine among patients in long-term treatment. 2023;44:41\u201350.","DOI":"10.1177\/08897077231165625"},{"key":"658_CR20","doi-asserted-by":"crossref","unstructured":"Arfken CL, Suchanek J, Greenwald MK. Characterizing fentanyl use in methadone-maintained clients. 2017;75:17\u201321. Available from: https:\/\/www.clinicalkey.es\/playcontent\/1-s2.0-S0740547216304731.","DOI":"10.1016\/j.jsat.2017.01.004"},{"key":"658_CR21","unstructured":"Organization WH. WHO\/UNODC\/UNAIDS position paper: substitution maintenance therapy in the management of opioid dependence and HIV\/AIDS prevention \/ World Health Organization, United Nations Office on Drugs and Crimes, UNAIDS [Internet]. World Health Organization; 2004. Available from: http:\/\/www.who.int\/iris\/handle\/10665\/42848."},{"key":"658_CR22","doi-asserted-by":"publisher","unstructured":"Best D, Gossop M, Stewart D, Marsden J, Lehmann P, Strang J. Continued heroin use during methadone treatment: relationships between frequency of use and reasons reported for heroin use. 1999;53:191\u20135. Available from: https:\/\/doi.org\/10.1016\/S0376-8716(98)00132-X.","DOI":"10.1016\/S0376-8716(98)00132-X"},{"key":"658_CR23","unstructured":"McInnes A. spring. Future of Canada\u2019s first-ever safer supply drug program uncertain with funding set to end in 2024; Available from: https:\/\/www.cbc.ca\/news\/canada\/london\/canada-safe-supply-london-ontario-federal-funding-1.7071004."},{"key":"658_CR24","doi-asserted-by":"publisher","unstructured":"Marshall AD, Schroeder SE, Lafferty L, Drysdale K, Baldry E, Stoov\u00e9 M et al. Perceived access to opioid agonist treatment in prison among people with a history of injection drug use: A qualitative study. 2023;150:209066. Available from: https:\/\/doi.org\/10.1016\/j.josat.2023.209066.","DOI":"10.1016\/j.josat.2023.209066"},{"key":"658_CR25","doi-asserted-by":"publisher","unstructured":"Giang V, Thulien M, McNeil R, Sedgemore K, Anderson H, Fast D. Opioid agonist therapy trajectories among street entrenched youth in the context of a public health crisis. 2020;11:100609. https:\/\/doi.org\/10.1016\/j.ssmph.2020.100609. PMID: 32613075; PMCID: PMC7317668.","DOI":"10.1016\/j.ssmph.2020.100609"},{"key":"658_CR26","unstructured":"Gomes T, Murray R, Kolla G, Leece P, Bansal S, Besharah J et al. Changing circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic [Internet]. Toronto, ON: Ontario Drug Policy Research Network; 2021. Available from: https:\/\/odprn.ca\/research\/publications\/opioid-related-deaths-in-ontario-during-covid\/."},{"key":"658_CR27","doi-asserted-by":"publisher","unstructured":"Holt M. Agency and dependency within treatment: Drug treatment clients negotiating methadone and antidepressants. 2007;64:1937\u201347. Available from: https:\/\/doi.org\/10.1016\/j.socscimed.2007.01.011.","DOI":"10.1016\/j.socscimed.2007.01.011"},{"key":"658_CR28","doi-asserted-by":"publisher","unstructured":"Cernasev A, Hohmeier KC, Frederick K, Jasmin H, Gatwood J. A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder. 2021;2:100029. Available from: https:\/\/doi.org\/10.1016\/j.rcsop.2021.100029.","DOI":"10.1016\/j.rcsop.2021.100029"},{"key":"658_CR29","doi-asserted-by":"crossref","unstructured":"Yarborough BJH, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. 2016;160:112\u20138. Available from: https:\/\/www.clinicalkey.es\/playcontent\/1-s2.0-S0376871616000028.","DOI":"10.1016\/j.drugalcdep.2015.12.031"},{"key":"658_CR30","unstructured":"Larkin M. Are Canada\u2019s safer supply programs in jeopardy? 2024; Available from: https:\/\/www.medscape.com\/viewarticle\/are-canadas-safer-supply-programs-jeopardy-2024a1000b3x?form=fpf."},{"key":"658_CR31","unstructured":"Public Health Ontario, Office of the Chief Coroner, Ontario Forensic Pathology Service, Ontario Drug Policy Research Network. Opioid mortality surveillance report: analysis of opioid-related deaths in Ontario July 2017-June 2018. [Internet]. Queen\u2019s Printer for Ontario. 2019. Available from: https:\/\/www.publichealthontario.ca\/en\/data-and-analysis\/substance-use\/opioid-mortality."},{"key":"658_CR32","doi-asserted-by":"crossref","unstructured":"Notley C, Holland R, Maskrey V, Nagar J, Kouimtsidis C. Regaining control: The patient experience of supervised compared with unsupervised consumption in opiate substitution treatment. 2014;33:64\u201370. Available from: https:\/\/api.istex.fr\/ark:\/67375\/WNG-8B87DLLW-0\/fulltext.pdf.","DOI":"10.1111\/dar.12079"},{"key":"658_CR33","doi-asserted-by":"crossref","unstructured":"Kolla G, Touesnard N, Gomes T. Addressing the overdose crisis in North America with bold action. 2022;117:1194\u20136. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/add.15844.","DOI":"10.1111\/add.15844"},{"key":"658_CR34","unstructured":"Smith JA. Reflecting on the development of interpretative phenomenological analysis and its contribution to qualitative research in psychology. 2004;1:39\u201354. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1191\/1478088704qp004oa."},{"key":"658_CR35","unstructured":"Indivior. SUBLOCADE\u2122 product monograph [Internet], Ottawa ON. Health Canada; 2022. Available from: https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=97349."},{"key":"658_CR36","doi-asserted-by":"crossref","unstructured":"Ning AM. Games of Truth: Rethinking Conformity and Resistance in Narratives of Heroin Recovery. 2005;24:349\u201382. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/01459740500334649.","DOI":"10.1080\/01459740500334649"},{"key":"658_CR37","doi-asserted-by":"crossref","unstructured":"Kourounis G, Richards BDW, Kyprianou E, Symeonidou E, Malliori M-M, Samartzis L. Opioid substitution therapy: Lowering the treatment thresholds. 2016;161:1\u20138. Available from: https:\/\/www.clinicalkey.es\/playcontent\/1-s2.0-S0376871615018360.","DOI":"10.1016\/j.drugalcdep.2015.12.021"},{"key":"658_CR38","doi-asserted-by":"publisher","unstructured":"Humphreys K, Shover CL, Andrews CM, Bohnert ASB, Brandeau ML, Caulkins JP et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford\u2013Lancet Commission. 2022;399:555\u2013604. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(21)02252-2.","DOI":"10.1016\/S0140-6736(21)02252-2"},{"key":"658_CR39","doi-asserted-by":"crossref","unstructured":"Hughto JMW, Tapper A, Rapisarda SS, Stopka TJ, Palacios WR, Case P et al. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs. 2023;18:30. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37217975.","DOI":"10.1186\/s13011-023-00538-x"},{"key":"658_CR40","unstructured":"Public Health Ontario. PHO Interactive Opioid Tool: Opioid-Related Morbidity and Mortality in Ontario [Internet]. 2023. Available from: https:\/\/www.publichealthontario.ca\/en\/data-and-analysis\/substance-use\/interactive-opioid-tool."},{"key":"658_CR41","doi-asserted-by":"publisher","unstructured":"Silverstein SM, Daniulaityte R, Martins SS, Miller SC, Carlson RG. Everything is not right anymore: Buprenorphine experiences in an era of illicit fentanyl. 2019;74:76\u201383. Available from: https:\/\/doi.org\/10.1016\/j.drugpo.2019.09.003.","DOI":"10.1016\/j.drugpo.2019.09.003"},{"key":"658_CR42","doi-asserted-by":"crossref","unstructured":"Frank D. I Was Not Sick and I Didn\u2019t Need to Recover: Methadone Maintenance Treatment (MMT) as a Refuge from Criminalization. 2018;53:311\u201322. Available from: http:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/10826084.2017.1310247.","DOI":"10.1080\/10826084.2017.1310247"},{"key":"658_CR43","doi-asserted-by":"publisher","unstructured":"Stone AC, Carroll JJ, Rich JD, Green TC. One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission. 2020;115:108031. Available from: https:\/\/doi.org\/10.1016\/j.jsat.2020.108031.","DOI":"10.1016\/j.jsat.2020.108031"},{"key":"658_CR44","doi-asserted-by":"crossref","unstructured":"Lin LA, Bohnert ASB, Blow FC, Gordon AJ, Ignacio RV, Kim HM et al. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. 2021;116:96\u2013104. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111%2Fadd.15116.","DOI":"10.1111\/add.15116"},{"key":"658_CR45","doi-asserted-by":"publisher","unstructured":"Mahu IT, Barrett SP, Conrod PJ, Bartel SJ, Stewart SH. Different drugs come with different motives: Examining motives for substance use among people who engage in polysubstance use undergoing methadone maintenance therapy (MMT). 2021;229:109133. Available from: https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109133.","DOI":"10.1016\/j.drugalcdep.2021.109133"},{"key":"658_CR46","doi-asserted-by":"crossref","unstructured":"Bass SB, Kelly PJA, Pandit-Kerr S, Pilla J, Morris K, Larsen E et al. It\u2019s my frenemy: A qualitative exploration of knowledge and perceptions of fentanyl use during the COVID-19 pandemic in people who use drugs at a syringe services program in Philadelphia, PA. 2022;10:882421. Available from: https:\/\/search.proquest.com\/docview\/2699959406.","DOI":"10.3389\/fpubh.2022.882421"},{"key":"658_CR47","unstructured":"Cahill TM. Methadone dosage and opioid overdose: A secondary analysis of supervised consumption site data. University of Ottawa; 2022. p. 103."},{"key":"658_CR48","unstructured":"Quenneville G. Supervised injection site closures come amid spike in overdose calls. 2024; Available from: https:\/\/www.cbc.ca\/news\/canada\/ottawa\/supervised-injection-site-closures-come-amid-spike-in-overdose-calls-1.7136626."},{"key":"658_CR49","doi-asserted-by":"publisher","unstructured":"Buresh M, Nahvi S, Steiger S, Weinstein ZM. Adapting methadone inductions to the fentanyl era. 2022;141:108832. Available from: https:\/\/doi.org\/10.1016\/j.jsat.2022.108832.","DOI":"10.1016\/j.jsat.2022.108832"},{"key":"658_CR50","doi-asserted-by":"crossref","unstructured":"Volkow ND. The epidemic of fentanyl misuse and overdoses: Challenges and strategies. 2021;20:195\u20136. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/wps.20846.","DOI":"10.1002\/wps.20846"},{"key":"658_CR51","unstructured":"Cheema K, Kahan M, Rodgers J, Smoke A, Turner S, Wyman J et al. Recommendations For Use of Slow-Release Oral Morphine as Opioid Agonist Therapy [Internet]. Toronto, ON: META:PHI; 2023. Available from: https:\/\/www.metaphi.ca\/wp-content\/uploads\/SROM.pdf."},{"key":"658_CR52","unstructured":"Hales J, Kolla G, Man T, O\u2019Reilly E, Rai N, Sereda A. Safer Opioid Supply Programs (SOS): A Harm Reduction Informed Guiding Document for Primary Care Teams [Internet]. 2020. Available from: https:\/\/bit.ly\/3dR3b8m."},{"key":"658_CR53","doi-asserted-by":"crossref","unstructured":"Magwood O, Salvalaggio G, Beder M, Kendall C, Kpade V, Daghmach W et al. The effectiveness of substance use interventions for homeless and vulnerably housed persons: A systematic review of systematic reviews on supervised consumption facilities, managed alcohol programs, and pharmacological agents for opioid use disorder. 2020;15:e0227298. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31945092.","DOI":"10.1371\/journal.pone.0227298"},{"key":"658_CR54","doi-asserted-by":"publisher","unstructured":"Leshner AI. Addiction is a brain disease, and it matters. 1997;278(5335):45\u20137. https:\/\/doi.org\/10.1126\/science.278.5335.45.","DOI":"10.1126\/science.278.5335.45"},{"key":"658_CR55","doi-asserted-by":"publisher","unstructured":"Valente PK, Bazzi AR, Childs E, Salhaney P, Earlywine J, Olson J et al. Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast. 2020;85:102934. Available from: https:\/\/doi.org\/10.1016\/j.drugpo.2020.102934.","DOI":"10.1016\/j.drugpo.2020.102934"},{"key":"658_CR56","volume-title":"Opioid Agonist Therapy: A Prescriber\u2019s Guide to Treatment","author":"P Selby","year":"2022","unstructured":"Selby P, Rieb L, Lam V, Zhang M, Bertram J. Opioid Agonist Therapy: A Prescriber\u2019s Guide to Treatment. Toronto, ON: Centre for Addiction and Mental Health; 2022."},{"key":"658_CR57","doi-asserted-by":"publisher","unstructured":"Santo T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. 2021;78:979\u201393. Available from: https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0976.","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"key":"658_CR58","doi-asserted-by":"crossref","unstructured":"Lachapelle \u00c9, Archambault L, Blouin C, Perreault M. Perspectives of people with opioid use disorder on improving addiction treatments and services. 2021;28:316\u201327. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/09687637.2020.1833837.","DOI":"10.1080\/09687637.2020.1833837"},{"key":"658_CR59","unstructured":"Dunham K, Kahan M, Wyman J. A guide to the use of depot buprenorphine [Internet]. Toronto, ON: META:PHI; 2023. Available from: https:\/\/www.metaphi.ca\/wp-content\/uploads\/Guide_DepotBuprenorphine.pdf."},{"key":"658_CR60","unstructured":"Dufour A. Northeastern Ontario\u2019s only supervised drug consumption site closing at end of June due to lack of funding. 2024; Available from: https:\/\/www.proquest.com\/docview\/3072710678\/abstract\/."},{"key":"658_CR61","doi-asserted-by":"publisher","unstructured":"Frank D. Methadone maintenance treatment is swapping one drug for another, and that\u2019s why it works: Towards a treatment-based critique of the war on drugs. 2020;83:102844. Available from: https:\/\/doi.org\/10.1016\/j.drugpo.2020.102844.","DOI":"10.1016\/j.drugpo.2020.102844"},{"key":"658_CR62","doi-asserted-by":"crossref","unstructured":"Jakobsen JS, Kloster ML, Christensen L, Johansen KS, Kappel N, Kronb\u00e6k M et al. Trade-offs in Substitution Treatment: A Qualitative Study of an Opioid Substitution Therapy Clinic as an Enabling and a Risk-Environment. 2022;49:64\u201383. Available from: https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/00914509211058988.","DOI":"10.1177\/00914509211058988"},{"key":"658_CR63","doi-asserted-by":"crossref","unstructured":"Damon W, Small W, Anderson S, Maher L, Wood E, Kerr T et al. \u2018Crisis\u2019 and \u2018everyday\u2019 initiators: A qualitative study of coercion and agency in the context of methadone maintenance treatment initiation. 2017;36:253\u201360. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/dar.12411.","DOI":"10.1111\/dar.12411"},{"key":"658_CR64","doi-asserted-by":"crossref","unstructured":"Bowles JM, McDonald K, Maghsoudi N, Thompson H, Stefan C, Beriault DR et al. Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications. 2021;18:1\u2013104. Available from: https:\/\/search.proquest.com\/docview\/2583197534.","DOI":"10.1186\/s12954-021-00546-9"},{"key":"658_CR65","doi-asserted-by":"crossref","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. It\u2019s like \u2018liquid handcuffs: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives. 2021;18:88. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34391436.","DOI":"10.1186\/s12954-021-00535-y"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00658-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00658-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00658-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T03:15:10Z","timestamp":1792379710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00658-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["658"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00658-2","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received ethical approval from both the University of Toronto (RIS Protocol #45839) and the Unity Health (REB #23\u2013108) Research Ethics Boards.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted as SC\u2019s Master\u2019s thesis at the Institute for Health Policy, Management and Evaluation at the University of Toronto under NP\u2019s supervision with KH and DW as committee members. MAP Centre for Urban Health Solutions (NP), Department of Family and Community Medicine, University of Toronto (NP), Department of Family and Community Medicine, St. Michael\u2019s Hospital, Unity Health Toronto (NP).","order":3,"name":"Ethics","label":"Authors\u2019 information","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"78"}}